Skip to main content

Table 3 Remission rate in each group by DAS28-ESR, CDAI, and SDAI

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Remission rate

PWs or HWs

TCZ-SC group, n (%)

csDMARDs-alone group, n (%)

Odds ratio for

TCZ-SC group/csDMARDs-alone group

(95% confidence interval)

P value

(TCZ-SC group vs csDMARDs-alone group)

DAS28-ESR

Overall

205.0 (67.9)

64.6 (21.7)

6.778 (4.508, 10.189)

< 0.0001

PWs

104.1 (66.3)

39.7 (25.5)

5.689 (3.146, 10.287)

< 0.0001

HWs

102.0 (70.3)

22.8 (16.1)

9.153 (4.814, 17.403)

< 0.0001

CDAI

Overall

125.5 (39.2)

58.5 (19.2)

2.549 (1.631, 3.982)

< 0.0001

PWs

62.4 (37.3)

43.0 (27.1)

1.564 (0.860, 2.845)

0.1427

HWs

70.2 (45.9)

16.1 (11.1)

5.635 (2.757, 11.516)

< 0.0001

SDAI

Overall

132.1 (41.8)

57.4 (19.1)

2.855 (1.828, 4.458)

< 0.0001

PWs

65.8 (40.1)

41.6 (26.5)

1.811 (0.991, 3.309)

0.0535

HWs

73.0 (48.1)

16.1 (11.3)

6.052 (2.981, 12.288)

< 0.0001

  1. Adjusted odds ratio by the logistic regression model using last observation carried forward; adjusted-weight analysis by inverse probability treatment weighting method
  2. Remission was defined as DAS28-ESR < 2.6, CDAI ≤2.8, and SDAI ≤3.3
  3. CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, HW house worker, PW paid worker, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection